Atlas Trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Clinical trial NCT02347657 · COMPLETED

Trial details

NCT number
NCT02347657
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2015-01-01
Primary completion
2017-01-20
Enrollment
510

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.